There are 30 anti-HIV drugs of 6 classes on the market, including NucleosideReverseTranscriptaseInhibitors (NRTIs), Non-NucleosideReverseTranscriptaseInhibitors (NNRTIs), ProteaseInhibitors (PIs), IntegraseInhibitors (IntegraseStrand), and Anti-HIV drugs. nucleosideReverseTranscriptaseInhibitors (NNRTIs), ProteaseInhibitors (PIs), IntegraseStrandTransferInhibitors (INSTIs), FusionInhibitors (FIs) (FusionInhibitor), and CCR5Antagonist.
Anti-HIV therapy must be administered in combination with a regimen that includes at least two drugs with different mechanisms of action, commonly two NRTIs and one NNRTI; or two NRTIs and two PIs (which contain ritonavir as an enhancer to slow down the metabolism of other PIs in the body and increase their blood levels). Current antiviral therapy cannot completely remove HIV from the organism, but after anti-HIV virus, the amount of virus in the organism can be suppressed to undetectable levels for a long time, and CD4+ T lymphocytes can be restored to some extent.
Since successful anti-HIV virus treatment can suppress the HIV virus in the infected person’s body for a long time to the extent of undetectable large, which can greatly reduce the transmission of HIV, anti-HIV treatment has been proposed in recent years as one of the means to prevent HIV transmission, and the universal accessibility of anti-HIV virus treatment drugs is advocated.